Side Effects of mRNA-Based COVID-19 Vaccines among Young Adults
(18–30 Years Old): An Independent Post-Marketing Study

J 2021

Side Effects of mRNA-Based COVID-19 Vaccines among Young Adults (18–30 Years Old): An Independent Post-Marketing Study

RIAD, Abanoub, Andrea POKORNÁ, Jitka KLUGAROVÁ, Natália ANTALOVÁ, Lucia KANTOROVÁ et. al.

Basic information

Original name

Side Effects of mRNA-Based COVID-19 Vaccines among Young Adults (18–30 Years Old): An Independent Post-Marketing Study

Authors

RIAD, Abanoub (818 Egypt, guarantor, belonging to the institution), Andrea POKORNÁ (203 Czech Republic, belonging to the institution), Jitka KLUGAROVÁ (203 Czech Republic, belonging to the institution), Natália ANTALOVÁ (703 Slovakia, belonging to the institution), Lucia KANTOROVÁ (703 Slovakia, belonging to the institution), Michal KOŠČÍK (203 Czech Republic, belonging to the institution) and Miloslav KLUGAR (203 Czech Republic, belonging to the institution)

Edition

Pharmaceuticals, Basel, MDPI, 2021, 1424-8247

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 5.215

RIV identification code

RIV/00216224:14110/21:00122615

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.3390/ph14101049

UT WoS

000715120800001

Keywords in English

BNT162 vaccine; COVID-19; Czech Republic; drug-related side effects and adverse reactions; mass vaccination; mRNA-1273 vaccine; phase IV; prevalence; young adult

Abstract

V originále

Young adults had been widely perceived as a low-risk group for COVID-19 severity; therefore, they were deprioritised within the mass vaccination strategies as their prognosis of COVID-19 infection is relatively more favourable than older age groups. On the other hand, vaccination of this demographic group is indispensable to achieve herd immunity. A cross-sectional survey-based study was used to evaluate the side effects of mRNA-based COVID-19 vaccines among university students in the Czech Republic. The validated questionnaire was delivered in a digital form, and it consisted of demographic data; COVID-19 vaccine-related anamnesis; and local, systemic, orofacial, and skin-related side effects’ prevalence, onset, and duration. Out of the 539 included participants, 70.1% were females and 45.8% were <23 years old. The vast majority (95.2%) reported at least one side effect. The most common side effect was injection site pain (91.8%), followed by fatigue (62.5%), headache (36.4%), and muscle pain (34.9%). The majority of local side effects occurred after both doses (74.4%), while most systemic side effects occurred after the second dose only (56.2%). Most local (94.2%) and systemic (93.3%) side effects resolved within three days after vaccination. Females participants’ adjusted odds ratio (AOR) showed they were 2.566 (CI 95%: 1.103–5.970) times more likely to experience post-vaccination side effects, and the participants who received two doses reported an increased AOR of 1.896 (0.708–5.077) for experiencing side effects. The results of this study imply that mRNA-based COVID-19 vaccines are highly probably safe for young adults, and further studies are required to investigate the role of medical anamnesis, prior COVID-19 infection, and gender in side effects incidence.

Links

LTC20031, research and development project

Name: Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic

Investor: Ministry of Education, Youth and Sports of the CR, INTER-COST

MUNI/A/1608/2020, interní kód MU

Name: Prohlubování znalostí v oblasti zdravotních rizik a benefitů výživy, prostředí a životního stylu III

Investor: Masaryk University

MUNI/IGA/1068/2020, interní kód MU

Name: Methodological and practical aspects of the development of guidelines and rapid guidelines in public health (Acronym: RAPguidelines-public-health)

Investor: Masaryk University

MUNI/IGA/1543/2020, interní kód MU

Name: Evidence-based Practice of Healthcare Professionals and Students in the Czech Republic (Acronym: Evidence-Based Practice in Czechia)

Investor: Masaryk University

Citovat

RIAD, Abanoub, Andrea POKORNÁ, Jitka KLUGAROVÁ, Natália ANTALOVÁ, Lucia KANTOROVÁ, Michal KOŠČÍK and Miloslav KLUGAR. Side Effects of mRNA-Based COVID-19 Vaccines among Young Adults (18–30 Years Old): An Independent Post-Marketing Study. Pharmaceuticals. Basel: MDPI, 2021, vol. 14, No 10, p. 1-16. ISSN 1424-8247. Available from: https://dx.doi.org/10.3390/ph14101049.

@article{1798797,
   author = {Riad, Abanoub and Pokorná, Andrea and Klugarová, Jitka and Antalová, Natália and Kantorová, Lucia and Koščík, Michal and Klugar, Miloslav},
   article_location = {Basel},
   article_number = {10},
   doi = {http://dx.doi.org/10.3390/ph14101049},
   keywords = {BNT162 vaccine; COVID-19; Czech Republic; drug-related side effects and adverse reactions; mass vaccination; mRNA-1273 vaccine; phase IV; prevalence; young adult},
   language = {eng},
   issn = {1424-8247},
   journal = {Pharmaceuticals},
   title = {Side Effects of mRNA-Based COVID-19 Vaccines among Young Adults (18–30 Years Old): An Independent Post-Marketing Study},
   url = {https://www.mdpi.com/1424-8247/14/10/1049},
   volume = {14},
   year = {2021}
}

TY  - JOUR
ID  - 1798797
AU  - Riad, Abanoub - Pokorná, Andrea - Klugarová, Jitka - Antalová, Natália - Kantorová, Lucia - Koščík, Michal - Klugar, Miloslav
PY  - 2021
TI  - Side Effects of mRNA-Based COVID-19 Vaccines among Young Adults (18–30 Years Old): An Independent Post-Marketing Study
JF  - Pharmaceuticals
VL  - 14
IS  - 10
SP  - 1-16
EP  - 1-16
PB  - MDPI
SN  - 14248247
KW  - BNT162 vaccine
KW  - COVID-19
KW  - Czech Republic
KW  - drug-related side effects and adverse reactions
KW  - mass vaccination
KW  - mRNA-1273 vaccine
KW  - phase IV
KW  - prevalence
KW  - young adult
UR  - https://www.mdpi.com/1424-8247/14/10/1049
N2  - Young adults had been widely perceived as a low-risk group for COVID-19 severity; therefore, they were deprioritised within the mass vaccination strategies as their prognosis of COVID-19 infection is relatively more favourable than older age groups. On the other hand, vaccination of this demographic group is indispensable to achieve herd immunity. A cross-sectional survey-based study was used to evaluate the side effects of mRNA-based COVID-19 vaccines among university students in the Czech Republic. The validated questionnaire was delivered in a digital form, and it consisted of demographic data; COVID-19 vaccine-related anamnesis; and local, systemic, orofacial, and skin-related side effects’ prevalence, onset, and duration. Out of the 539 included participants, 70.1% were females and 45.8% were <23 years old. The vast majority (95.2%) reported at least one side effect. The most common side effect was injection site pain (91.8%), followed by fatigue (62.5%), headache (36.4%), and muscle pain (34.9%). The majority of local side effects occurred after both doses (74.4%), while most systemic side effects occurred after the second dose only (56.2%). Most local (94.2%) and systemic (93.3%) side effects resolved within three days after vaccination. Females participants’ adjusted odds ratio (AOR) showed they were 2.566 (CI 95%: 1.103–5.970) times more likely to experience post-vaccination side effects, and the participants who received two doses reported an increased AOR of 1.896 (0.708–5.077) for experiencing side effects. The results of this study imply that mRNA-based COVID-19 vaccines are highly probably safe for young adults, and further studies are required to investigate the role of medical anamnesis, prior COVID-19 infection, and gender in side effects incidence.
ER  -

RIAD, Abanoub, Andrea POKORNÁ, Jitka KLUGAROVÁ, Natália ANTALOVÁ, Lucia KANTOROVÁ, Michal KOŠČÍK and Miloslav KLUGAR. Side Effects of mRNA-Based COVID-19 Vaccines among Young Adults (18–30 Years Old): An Independent Post-Marketing Study. \textit{Pharmaceuticals}. Basel: MDPI, 2021, vol.~14, No~10, p.~1-16. ISSN~1424-8247. Available from: https://dx.doi.org/10.3390/ph14101049.

Detailed Information on Publication Record